2024
1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials
BJORNSTAD P, DANNE T, TAMBORLANE W, KLINGENSMITH G, SCHUELER E, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S, LAFFEL L. 1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials. Diabetes 2024, 73 DOI: 10.2337/db24-1140-p.Peer-Reviewed Original ResearchDiabetic kidney diseaseKidney diseaseHoc analysisDiabetic kidney disease riskEarly diabetic kidney diseaseBaseline to weekImpact of empagliflozinCystatin C equationClinically relevant improvementNational Institute of DiabetesDigestive and Kidney DiseasesPost hoc analysisEGFR changeIncreased riskHyperfiltrationPubertal statusGlycemic controlEGFRC equationLong-term effectsPotential long-term effectsRelevant improvementNormofiltrationT2DHealthy youth
2010
The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T, . The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care 2010, 33: 1269-1274. PMID: 20332354, PMCID: PMC2875436, DOI: 10.2337/dc09-2042.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioContinuous glucose monitoringType 1 diabetic patientsImproved glucose controlCost-effectiveness analysisGlucose controlDiabetic patientsGlucose monitoringBenefits of CGMType 1 diabetes complicationsTest strip useType 1 diabetesCost-effectiveness ratioStandard glucose monitoringMicrovascular complicationsDiabetes complicationsTrial populationSocietal cost-effectiveness analysisGlycemic benefitsLong-term effectsMAIN OUTCOMELife benefitsQALY thresholdStrip useTrial data